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Abstract
To analyze contemporary costs of HIV health care and the cost distribution across lines of combination antiretroviral therapy (cART).
To identify variations in expenditures with patient characteristics and to identify main cost determinants. To compute cost ratios
between patients with varying characteristics.
Empirical data on costs are collected in Germany within a 2-year prospective observational noninterventional multicenter study.
The database contains information for 1154 HIV-infected patients from 8 medical centers.
Means and standard deviations of the total costs are estimated for each cost fraction and across cART lines and regimens. The
costs are regressed against various patient characteristics using a generalized linear model. Relative costs are calculated using the
resultant coefficients.
The average annual total costs (SD) per patient are €22,231.03 (8786.13) with a maximum of €83,970. cART medication is the
major cost fraction (83.8%) with a mean of €18,688.62 (5289.48). The major cost-driving factors are cART regimen, CD4-T cell
count, cART drug resistance, and concomitant diseases. Viral load, pathology tests, and demographics have no significant impact.
Standard non-nucleoside reverse transcriptase inhibitor-based regimens induce 28% lower total costs compared with standard PI/r
regimens. Resistance to 3 or more antiretroviral classes induces a significant increase in costs.
HIV treatment in Germany continues to be expensive. Majority of costs are attributable to cART. Main cost determinants are CD4-T
cells count, comorbidity, genotypic antiviral resistance, and therapy regimen. Combinations of characteristics associated with higher
expenditures enhance the increasing effect on the costs and induce high cost cases.
Abbreviations: ALT = alanine aminotransferase, ARV = antiretroviral, cART = combination antiretroviral therapy, CCR5 = C-C
chemokine receptor type 5, CDC = Centers for Disease Control and Prevention classification system, CORSAR = Cost and
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1. Introduction age, gender, education, and income status; (ii) clinical conditions:2.
3.
4.
5.The introduction of combined antiretroviral (ARV) therapy and
its successful scale-up have resulted in major reductions in HIV-
associated morbidity and mortality,[1–3] and transformed HIV
into a chronic and manageable condition.[4] cART regimens have
been proven effective and well tolerated, and have become the
standard in HIV-related health care[4–6]; however, cART is
expensive and together with the growing number of people living
with HIV, who receive cART and their prolonged life expectancy,
it poses an increasing financial burden on public health systems.
Continuous accurate estimations of the related costs have become
important for decision-making in management of HIV infec-
tion.[7] Estimates of annual total expenditures per patient have
been obtained worldwide[8–13]; however, in Germany relatively
few studies have investigated costs of HIV treatment since the
advent of cart.[8,14–16] For the period from 2006 to 2009, mean
average costs for Germany were estimated as € 23,298 per
patient.[14] It has been determined that patient characteristics,
such as CD4-T cell count are good predictors of annual costs;
however, the authors point to a need for further research in this
field.[7,14]
The objective of the present study is to explore links between
costs and a wide set of patient characteristics using data, which
were collected within a 96 weeks noninterventional, multicenter
prospective cohort study: Cost and Resource Utilization Study in
Antiretroviral Therapy (CORSAR).[16] Previously, we conducted
a descriptive analysis of the cost data obtained over the first 48
weeks of this survey.[16]
In this analysis, we examine composition of the annual costs,
determine major cost drivers,[17] and estimate relative cost
ratios[18] between patients with varying characteristics. The
relative cost ratios, in comparison to point estimates, have the
advantage of possible stability across various populations, and




2.1. Setting and study design
Themulticenter CORSAR study recruited patients in 8 regionally
and structurally different health care providers from different
areas in Germany for a prospective noninterventional survey
from 2009 to 2012: 4 specialized private practices (outpatient
centers) and 4 hospitals offering both HIV-related inpatient and
outpatient services. The multicenter design and absence of
preselection minimized a risk of bias.
Major criteria for enrolment of the patients to the survey were
HIV-positive status, age older than 18 years, and ongoing cART.
At the beginning of the survey, the participating sites recorded full
patient data as at the date of individual entry to the study;
thereafter, the observation and recording of the data were
documented every 3 months on an individual schedule. The
resultant database provided information on (i) demographics:diagnosis, time after initial diagnosis ofHIV infection, CD4-T cell
count, Centers for Disease Control and Prevention classification
system (CDC) class, viral load, pathology tests, disability, and
comorbidities; (iii) therapy: therapeutic regimen (dosage, sub-
stances, and treatment periods), line of ARV regimen at start of
the study, genotypic resistance testing, and details of concomitant
medications.
The following classifying parameters were assigned to the
patients at the date of entry and were not changed during the
follow-up period: age, CDC classification, time since the initial
diagnosis of HIV before entering the study, assigned therapy
regimen, and cART therapy line.
For the analysis, ARV regimens were classified according to the
classes of the ARV substances (further references to the defined
here ARV regimens are highlighted in Italic format and used for
the purpose of the present analysis only):
1. “NNRTI” (non-nucleoside reverse transcriptase inhibitor):
NNRTI-based regimen, consisting of 1 NNRTI in addition to
nucleos(t)ide analogues;
“PI-standardized”: PI-based regimen, consisting of 1 ritona-
vir-boosted PI (Protease inhibitor, PI/r) in addition to nucleos
(t)ide analogues;
“PI-individualized”: individualized PI/r-based cART regimens
consisting of elements of more than 2 different ARV classes
and more than 3 different ARV substances including boosted
PIs (predominantly used as a salvage regimen in multiple pre-
treated patients);
“Other”: other cART regimens that do not meet the criteria of
the 3 previous regimen classes, that is, regimens that consist
neither of PI nor NNRTI elements, that is, those based on the
INSTI (integrase strand transfer inhibitor) raltegravir or the
CCR5 (C-C chemokine receptor type 5) inhibitor maraviroc,
nor nuke-sparing regimens, for example, boosted double PI/r
therapy;
“Mixed”: if patients spent less than 95% of the year on one of
the aforementioned regimen classes, their therapy classes were
classified as “Mixed.”
2.2. Ethical review
The CORSAR survey was approved by the national regulatory
authorities and local ethics committees of all participating
centers. All patients were given thorough information on the
survey. Before the participation in the interviews, the patients
gave a written consent. No incentive was offered for the
participation in the survey.The collected data contained detailed information on utilization
of various resources, including (i) cARTmedication and non-HIV
medication; (ii) outpatient care (physicians’ services, outpatient
rehabilitation, nutritional, and psychological support); (iii)
inpatient care (hospital stay, inpatient costs, rehabilitation, 65 people who abandoned the survey during the first year and
Treskova et al. Medicine (2016) 95:26 www.md-journal.comphysiotherapy, and overhead expenses); (iv) indirect costs; and
(v) out-of-pocket costs.
The expenditures were calculated by taking the volume of
resource utilization for inpatient days, outpatient specialist visits,
lab tests, usage of in- and outpatient rehabilitation, and services
of nutritionists and psychologists, and multiplying these by the
respective unit cost in accordance with the current German
recommendations for the assessment of health care resource
consumption.[19,20] Following these recommendations,[20] we
calculated drug costs taking pharmacy retail prices and
subtracting manufacturer and pharmacy discounts paid to the
statutory health insurance.
We estimated the unit cost of an inpatient stay based on
German hospital statistics.[21] The calculation of in- and
outpatient rehabilitation unit cost was performed using data
from the statutory health insurance fund, retirement insurance,
and the Federal Association for Rehabilitation.[22–24] Data on
the unit cost for a specialist visit were retrieved from the salary
report provided by the German Association of Statutory
Health Insurance Doctors.[25] Publically available reports on
supportive medical care were used in estimating the unit cost for
massages and physiotherapy services.[26–28] Indirect costs were
calculated as the product of number of days of absence from
work and work compensation per day. To avoid overestimation
of the indirect costs of early retirements or permanent
occupational disability, we put an upper limit to the days of
absence fromwork equal to the vacancy time of jobs in Germany
in 2012 (77 days).[20] This approach is a simplification of the
friction costs approach.[29]
Cumulative annual costs were calculated prospectively by
annualization. Total costs were computed as the sum of the cost
fractions following a bottom-up method.2.4. AnalysisTotal costs were analyzed separately for each year of the
observational period. We excluded from the obtained data all
individuals on treatment break, all patients who had abandoned
the survey during the first year, and those patients who incurred
extremely high expenditures on non-HIV medication (over
€100,000/year). We defined proportions for each of the cost
components and analyzed the variation of the total costs across
the patient variables. We calculated means and standard
deviations of the total costs as well as the costs in each fraction.
In order to estimate mean annual costs as a function of various
patient characteristics, we employed different multiple regression
models. We developed the models based on distributional
characteristics of the cost data and selected the best-fitting
model using McFadden’s pseudo-R2 and measures of prediction
ability.[30] We used the obtained estimates to calculate cost
ratios[18] that allowed the comparison of cost projections for
patients with varying indicative characteristics while holding
others unchanged. Detailed description of the model develop-
ment and estimation of the cost ratios are given in Appendix A
(see Appendix A and to that related Table 9, Table 10, and
Figures 2–5, Supplemental Content, http://links.lww.com/MD/
B55, which describe the applied methods in greater detail).3. ResultsOverall, CORSAR enrolled 1154 adult patients. In total, we
excluded 132 patients: 63 people with treatment interruptions,3
4 patients who incurred extremely high expenditures on
non–HIV-related medications. Eighty patients did not follow
the survey into the second year. The resulting sample was of 1022
patients who had completed the first year and 942 who had
completed both years of the survey, totally resulting in 1964
patient years.
Table 1 reports details on the patient data and estimates of
the average annualized total costs stratified across clinical and
demographic variables.
The patient data for subjects lost to follow-up during the first
year of the study are given in supplement (see Table 6,
Supplemental Content, http://links.lww.com/MD/B55) and show
no particular differences from the rest sample. Results of the
descriptive analysis of the costs do not show a considerable
difference between the estimates obtained for the first and the
second year as well as there were no significant differences in
the cost of HIV care across the 8 health care provider sites
in the survey. For the first and the second year, the mean annual
total costs (SD) per patient were €22,477.57 (8809.45) with a
maximum of €87,920, and €22,231.03 (8786.13) with a
maximum of €83,970, respectively. cART medication was found
to be the major contributor (83.8%) to the total costs with mean
(SD) of €18,852.53 (5297.44) in the first and €18,688.62
(5289.48) in the second year. The second largest fraction was
medication costs on treatment of comorbidities with mean values
of €1499.36 (3718.50) and €1805.05 (5034.45) and for the first
(6.6%) and second (8.1%) years, respectively. Expenditures on
inpatient care were estimated as €1246.98 (3850.15) and
€984.53 (2894.06) and contributed 5.6% and 4.4% into the
total costs, respectively. Further data on costs stratified by
therapy line and therapy class are given in Table 2 for both years.
Tables presenting the cost data across the 8 health care
providers stratified by cost categories (see Table 7, Supplemental
Content, http://links.lww.com/MD/B55) and annualized costs of
HIV care by cost category for both years of CORSAR(see
Table 8, Supplemental Content, http://links.lww.com/MD/B55)
are given in the supplemental content.
The regression analysis was performed using the full patient
data collected at the beginning of the survey and data on
expenditures obtained over the following 1-year period of the
CORSAR survey (n=1022; Table 1). Patients with CD4-T count
below 200cells/mm3 incur the highest total costs, cART
medication costs, and inpatient costs compared with those for
patients with less advanced cellular immunodeficiency. Table 3
reports mean (SD) total costs for each therapy line and therapy
class stratified by CD4-T cell count showing the same pattern of
variability of the costs for different disease stages across therapy
classes and cART lines.
As assessed by 1-way analyses of variance, overall differences
in mean total costs were statistically significant across the
categories of the following variables: CD4-T cell count, plasma
viral load of HIV, genotypic antiviral resistance, comorbidity,
ARV therapy line, and therapy class.
We regressed the annual total costs against 14 explanatory
variables using a generalized linear model (GLM) with a log link
function and inverse Gaussian distribution of the error term.[31]
The estimates with 95% confidence intervals resulting from
fitting the model are given on a log scale in Table 4.
Exponentiating the value of the intercept gives an estimate of
the mean total costs for a hypothetical patient with the reference
characteristics as €22,959.80. All estimates represent the mean
differences in total costs relative to these control categories.
Table 1








Age group Age group of a patient in years 20–29 2.45 20433.52 (5832.53)
30–44 35.03 21204.40 (7139.14)
45–59 48.43 23293.55 (9619.25)




Gender Gender Female 11.15 21135.21 (7313.19)
Male 88.16 22631.30 (9001.27)
n.a. 0.68
Education The highest educational level achieved Graduated 17.22 22899.59 (9874.76)
‘ Neither nor 69.57 22593.78 (8792.30)
No school certificate 1.86 22257.89 (5689.44)
n.a. 11.35
Income Stable or nonstable income Full-time employment 36.89 22109.67 (9331.49)
Pensioner 26.22 24353.18 (9792.38)
Other 23.48 21553.61 (7067.69)
n.a. 13.41
HIV-related variables
Time since diagnosis of HIV Time after initial diagnosis of HIV infection
before entering the survey (in years)
0–10 45.89 20887.23 (6546.21)
10–20 33.37 22856.04 (9426.28)
>20 10.96 26947.46 (12355.37)
n.a. 9.78
CDC class Class according to the CDC classification
system for HIV infection
Category A: Mildly symptomatic 29.26 20444.96 (6887.97)
Category B: Moderately symptomatic 43.25 23013.70 (8742.01)
Category C: Severely symptomatic 27.50 23759.40 (10400.28)
n.a. 0.00
Viral load HIV viral load (RNA copies/mL) <50 85.23 22114.38 (8523.27)
50–500 6.36 24674.51 (10423.58)
>500 2.05 26808.55 (16209.45)
n.a. 6.36
CD4-T CD4-T cell count (cells/mm3) >500 55.09 22014.91 (8559.18)
200–500 38.36 22203.99 (8151.42)
<200 6.46 27960.86 (12774.61)
n.a. 0.10
Treatment-related variables
Therapy class Assigned antiretroviral drugs classes PI-ind 5.58 38333.72 (13250.53)
PI-standard 40.90 25057.94 (6769.53)
NNRTI 26.52 18221.90 (5457.26)
Mixed 7.63 22575.21 (9796.56)
Other 19.37 18295.04 (7014.85)
n.a. 0.00
Therapy line Combination antiretroviral therapy (cART) line First line 42.27 21182.04 (7193.05)
Second and third line 17.03 21259.52 (7562.71)
Beyond the third line 27.89 25285.13 (10824.55)
n.a. 12.82
Resistance Genotypic resistance against
antiretroviral medication
No resistance 82.58 21737.98 (8164.37)
Three classes (PI, NNRTI, and NRTI) and more 4.31 16546.00 (4625.89)
NNRTI 0.20 27411.45 (11468.56)
NRTI 1.08 27876.00 (10467.59)
NRTI and NNRTI 0.49 23194.37 (9335.68)
PI 7.63 23491.32 (9016.87)
PI and NRTI 3.72 32670.73 (12439.09)
n.a. 0.00
General health-related variables
ALT test Alanine aminotransferase test (U/L) <110 94.81 22454.79 (8787.94)
≥110 2.64 24926.26 (11215.06)
n.a. 2.54
LDL test Low-density lipoprotein cholesterol test (mg/dL) <200 76.91 22645.74 (8996.35)
≥200 1.96 22207.95 (4438.80)
Treskova et al. Medicine (2016) 95:26 Medicine
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Creatinine test Serum creatinine level test (mg/dL) < 0.9 49.12 21853.01 (8385.95)
0.9–1.5 46.67 23165.05 (8911.07)
>1.5 1.66 28518.82 (17065.95)
n.a. 2.54
Comorbidity Number of concomitant diseases and degree
the severity of the severest among the diseases
2non-severe 33.46 21153.69 (8564.13)
2 severe 8.61 24335.64 (9100.47)
>2 nonsevere 25.05 21886.39 (7486.47)
>2 severe 4.01 28704.37 (14693.85)
None 28.86 21004.24 (8180.29)
n.a. 0.00
Disability Disability index according to the
German the Disabled Persons Act†
0—No disability 50.39 21206.26 (7834.82)
<50—Intermediate/moderate disability 11.35 22169.72 (8152.56)
≥50—Severe disability in activities of daily living 28.96 24762.82 (10245.40)
n.a. 9.30
ALT = alanine aminotransferase; CDC = Centers for Disease Control and Prevention classification system; HIV = human immunodeficiency virus; LDL = low-density lipoprotein cholesterol; NNRTI =
non-nucleoside reverse transcriptase inhibitor; PI = protease inhibitor.
∗
Not available observations.
† Grad der Behinderung (GdB), Deutsches Schwerbehindertenrecht.
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count, genotypic resistance against ARV medication, and a
greater number and severity of concomitant diseases were strong
predictors of more intensive health care utilization and increased
treatment costs. Higher costs were induced by the following levels
of the predictors: evidence of cellular immunodeficiency at entry
to CORSAR (“CD4-T cell count between 200 and 500/mm3” or
“less than 200/mm3”) vs. nonimpaired immune status (“more
than 500/mm3”), disability with index “>50” versus index “0,”
comorbidity classified as more than 2 nonsevere concomitant
diseases and more than 2 severe concomitant diseases versus
control category of fewer than 2 nonsevere concomitant diseases,
therapy class defined as “PI-individualized” versus “PI-stan-
dardized,” drug resistance to PI-based regimens or to 3 or more
ARV classes versus no genotypic resistance.
The following categories of the predictors were associated with
lower costs relative to the control categories: female gender,
“10–20 years” versus “0–10 years” after the first positive
diagnosis of HIV infection, a laboratory test of blood creatinine
with level of “>1.5” versus “<0.9,” therapy class of “NNRTI,”
“Mixed,” and “Other” category versus “PI-standardized”
category. Age, CDC-class, laboratory tests low-density lipopro-
tein (LDL) and alanine aminotransferase (ALT), and viral load
did not appear to have a significant effect on the total costs within
the study.
Using the obtained estimates, we calculated cost ratios between
patients with different characteristics.[18] Assuming all other
patient characteristics being held constant, cost ratios were
estimated relative to the following comparison group: “male”
gender, “PI-standardized” therapy class, “<500” CD4-T cell
count, comorbidity of fewer than 2 nonsevere diseases, no drug
resistance. The ratios were calculated across genders, all CD4-T
cell strata, all therapy classes, and 2 categories of drug resistance:
resistance to at least 3 therapy classes and no resistance. Figure 1
illustrates calculated cost ratios. The values of the ratios and
respective confidence intervals are given in Table 5.
The relative costs show either increasing or decreasing effects
of the selected categories of the patients characteristics on the
costs in terms of factors relative to the reference case, and can becharacteristics.
The cost ratios show an enhanced increasing effect of a
combination of the patient characteristics associated with higher
costs. For instance, for those with resistance to 3 or more ARV
classes the costs increase by a factor of 1.266. For those with
combination of this resistance with a complex individualized
cART regimen, the costs increase by a factor of 1.818. Adding to
this combination a low CD4-T cell count and severe comorbidity
increases the costs by more significant factors: of 2.202 and
2.722, respectively.The strength of CORSAR is that it provides recent cost-of-disease
data of HIV infection in a prospective, multicenter study design
within a large national cohort in Germany, representing different
structures of the German health care providers. It reflects the
actual state of cART for patients in different stages of HIV disease
and on different ARV treatment lines, including more recently
approved ARVs, complies with current treatment guidelines, and
takes into account actual price changes in the cART medication
during the observation period. Additionally, the present work
gains an advantage with estimating the cost ratios that can be
applicable for other populations.
The estimated average annual total costs per patient
(€22,231.03) are slightly lower comparing with the results of
Mostardt et al (€23,298)[14] who conducted their study in
Germany, using 2008 as the price reference year. As well as, our
estimates fall into ranges of estimates provided in different studies
conducted in the United States[7,32,33] and European countries.[8]
Overall, comparison of the results between the studies should
be done cautiously due to considerable differences in the design
of the observational surveys and the resultant population
samples.
The proportion of cART costs in total costs has risen from
about 67% to about 84% and the fraction of inpatient care costs
has decreased from the level estimated in 2001,[34] suggesting a
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Mean cART costs are higher for first-line therapy compared Germany before 2013. The predominance of PI/r-based cART
Table 3
Mean annualized total costs (SD) by CD4-T cells count stratum, the therapy line, and the therapy class.
Mean of total costs (SD) across combination antiretroviral therapy lines stratified by CD4-Tcell count (n=1022; Euro)
CD4–T cells/mm3 The first The second and the third Beyond the third
>500 21551.78 (8152.84) 20739.94 (7130.33) 23911.55 (10345.39)
200–500 20609.06 (5824.29) 21056.82 (7239.24) 26060.39 (10305.20)
<200 22592.92 (7701.60) 27489.64 (10824.19) 32418.55 (14193.73)
Mean of total costs (SD) across antiretroviral drugs classes stratified by CD4-T-cell count (n=1022; Euro)
CD4–T cells/mm3 PI-ind PI-stand NNRTI Mixed Other
>500 37762.54 (13829.54) 25234.02 (7661.74) 17569.25 (4773.33) 20696.30 (6837.91) 17445.12 (4510.64)
200–500 37407.90 (12499.68) 24476.15 (5203.15) 18993.48 (6276.20) 21702.12 (9941.09) 18020.45 (6544.42)
<200 42763.12 (13935.73) 27503.20 (5701.21) 20455.50 (5685.62) 28441.08 (15167.92) 26177.79 (15844.88)
NNRTI = non-nucleoside reverse transcriptase inhibitor; PI = protease inhibitor.
Treskova et al. Medicine (2016) 95:26 www.md-journal.comwith second- and third-line therapies. The difference is a
consequence of the applied ARV regimens: PI/r or INSTI-
based regimens were commonly used in first-line therapy and
were more expensive than NNRTI-based cART regimens,
which were widely applied in second- or third-line cART inTable 4
Summary of the regression analysis for annualized total costs (GLM
function; n=1022).
Predictor/reference category Comparative category E
Intercept 1




Disability/none (index “0”) “< 50”
“≥ 50”
CDC class/B A 
C 
Therapy line/the first line Beyond the third
The second and the third
Lab ALT/< 110 ≥110 
Lab CREAT/<0.9 > 1.5 
0.9–1.5 
Lab LDL/<200 ≥ 200 




Viral load/<50 > 500
50–500 
CD4-T cells count/>500 200
200–500
Time since diagnosis/0–10 years 10–20 years 
>20 years










ALT = alanine aminotransferase; CDC = Centers for Disease Control and Prevention classification system
PI = protease inhibitor.






”, 0.05; “.”, 0.1; “ ”, 1.
7
in first-line therapy has been previously described in theGerman
Clin-Surv cohort and explained by the assumption of an
elevated risk of virologic failures and selection for viral
resistance by NNRTIs in cART-naïve patients with a high viral
load.[34]with inverse Gaussian distribution of the error term and log link




0.0925 0.0716 0.2567 0.2698
0.0012 0.0510 0.0533 0.9647
0.0140 0.0898 0.0618 0.7177
0.0891
∗ 0.0170 0.1611 0.0157




0.0398 0.0149 0.0945 0.1540
0.0545 0.0053 0.1143 0.0747
0.0334 0.0954 0.0287 0.2926
0.0555 0.1212 0.0102 0.0984
0.0712 0.0683 0.2107 0.3178
0.2205
∗ 0.0435 0.3975 0.0150
0.0119 0.0370 0.0609 0.6335
0.0150 0.1517 0.1818 0.8598







0.0381 0.0990 0.0228 0.2204
0.0995 0.2895 0.0905 0.3051




0.0474 0.0969 0.0022 0.0615
0.0573
∗ 0.0004 0.1143 0.0491




0.0711 0.4326 0.5748 0.7820
0.0523 0.3056 0.2009 0.6855
0.2837 0.7547 0.1873 0.2383
0.0742 0.1546 0.0062 0.0710





∗∗∗ 0.2643 0.3835 <0.001
0.1849
∗∗∗ 0.0857 0.2841 <0.001
0.3079
∗∗∗ 0.2462 0.3695 <0.001
; LDL = low-density lipoprotein cholesterol; NNRTI = non-nucleoside reverse transcriptase inhibitor;
The second- and third-line therapies, however, are associated concomitant diseases or both. In contrast to these subgroups,
Figure 1. Spider web plot of cost ratios between patients with varying characteristics. Points on the axis give either increasing or decreasing effects of the
presented groups of patient characteristics relative to the reference case for men (left) and women (right). Point types represent the respective therapy classes. The
blue rhombus in the middle of the plot (left) gives the reference case, which corresponds to a cost ratio of 1 and the following characteristics: male, therapy
class= “PI-stand,”CD4= “>500,” comorbidity= “2 nonsevere,” drug resistance= “no resistance.” All other ratios (including those given on the plot for women) are
presented relative to the reference case. Res, drug resistance; CD4, CD4-T cells count group; Com, comorbidity (categories are described in Table 1).
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with higher utilization of nonmedicationHIV care: hospital stays,
outpatient care, and rehabilitation. Higher health care services
consumption is mainly caused by occurrence of intercurrent
diseases or immune reconstitution inflammatory diseases among
late-presenting patients with HIV in the first years after initiation
of cart.[35,36] Patients under therapy beyond the third-line report
the highest direct costs for cART medication, these being driven
by more complex ARV treatment regimens: a higher amount of
used substances and increased doses of certain ARVs. Although it
was not documented in CORSAR, it is reasonable to suggest that
switching to a beyond the third-line therapy might be induced
either by treatment failures or strategic aspects of ARV treatment
or by an intention to overcome adverse long-term effects or
individual intolerances against certain ARVs.
The modeling methods applied in this study reveal possible
determinants of the average annual costs per patient. Mean total
costs increase with a decline in CD4-T cell count. This result is
consistent with findings of other studies[7,14]; however, when
considering the clinical stage, CDC classification variable,
particularly class C, which defines the AIDS stage, shows an
absence of statistically significant estimates. It suggests that long-
term surviving the AIDS stage does not impact on annual costs;
thus, only actual CD4-T cell count below 200/mm3 is a strong
predictor of higher costs due to the higher risk of related
infections and diseases. This observation might be relevant to 3
different patient subgroups in the CORSAR cohort: (i) late
presenters with advanced cellular immunodeficiency who
recently started cART, (ii) patients with an immunological or
clinical failing of cART, and (iii) immunological long-term
nonresponders, usually late presenters, who started cART with a
profound cellular immunodeficiency with a CD4-T cell count
below 50/mm3. All 3 subgroups have a higher risk of receiving a
more advanced cART treatment line or to have intercurrent orthose late presenters who have been receiving cART for more
than 1 or 2 decades and belong to the CDC-C class, but
have actual CD4-T cell counts within the normal range, are more
likely to receive less complex cART or to have no active
concomitant diseases. Female patients incur fewer costs than
male patients. These differences have been previously reported
elsewhere.[14,37–39] One might hypothesize a number of reasons
for gender-specific differences in costs[14]; in our study,
considerable differences lie in expenditures on non–HIV-related
medication and indirect costs.
We also found an association between costs and the presence of
concomitant diseases and disability. The source of these
increasing total costs is expenditures on non-HIV medication
and additional care. According to the estimated cost ratios,
worsening of comorbidity, in terms of number of diseases and
their severity, induces a considerable rise in annual total costs. In
the CORSAR database, the reported concomitant diseases are
grouped into: cardiovascular, respiratory, gastrointestinal,
endocrine, neurological, psychiatric, dermatological, hematolog-
ical, and allergological diseases. Defining cost variation across
types of concomitant diseases requires additional data and
further analysis.
With regard to the therapy-related predictors, the total costs
are linked to the cART regimens, costs of which are directly
related to drug prices and the number of ARVs used; when
holding all other factors constant, variation of the therapy class
from PI/r-based cART to NNRTI-based treatment which is
available as a less expensive alternative in Germany[40] decreases
annual costs in the CORSAR cohort. However, individual risks
of treatment failure, development of drug resistance or occur-
rence of toxicity are not modeled in this study; therefore, the
impact of these events on the resulting costs in long term cannot
be defined. Additionally, the total costs increase when drug
resistance occurs; average total costs are particularly responsive short-term progression of HIV infection. Further studies with a
Table 5
Estimated cost ratios relative to the comparison group (male individuals with therapy class “PI-stand,” CD4=“>500,” comorbidity=
“2 nonsevere,” and drug resistance=“no resistance”), 95% confidence intervals in parentheses.
Patient characteristics Comorbidity PI-stand PI-indiv NNRTI Mixed Other
Male. No resistance. CD4: >500 2 nonsevere 1.000∗ 1.436 (1.249,1.652) 0.723 (0.681,0.767) 0.831 (0.753,0.918) 0.735 (0.691,0.781)
>2 nonsevere 1.082 (1.016,1.151) 1.553 (1.330,1.814) 0.782 (0.471,1.230) 0.899 (0.798,1.012) 0.795 (0.730,0.865)
>2 severe 1.236 (1.093,1.397) 1.775 (1.466,2.148) 0.894 (0.778,1.027) 1.027 (0.874,1.207) 0.908 (0.793,1.034)
Male. No resistance. CD4: 200–500 2 nonsevere 1.049 (0.998,1.102) 1.506 (1.301,1.743) 0.758 (0.703,0.817) 0.871 (0.781,0.972) 0.771 (0.713,0.833)
>2 nonsevere 1.134 (1.045,1.231) 1.629 (1.384,1.916) 0.820 (0.742,0.907) 0.943 (0.829,1.072) 0.834 (0.754,0.921)
>2 severe 1.296 (1.133,1.482) 1.861 (1.528,2.267) 0.937 (0.808,1.087) 1.077 (0.909,1.276) 0.953 (0.824,1.102)
Male. No resistance. CD4: < 200 2 nonsevere 1.211 (1.085,1.350) 1.740 (1.461,2.071) 0.876 (0.772,0.994) 1.007 (0.872,1.162) 0.890 (0.788,1.006)
>2 nonsevere 1.310 (1.151,1.491) 1.882 (1.557,2.273) 0.948 (0.821,1.094) 1.089 (0.928,1.278) 0.963 (0.838,1.106)
>2 severe 1.497 (1.273,1.760) 2.150 (1.734,2.665) 1.083 (0.909,1.290) 1.244 (1.032,1.501) 1.100 (0.930,1.302)
Male. Resistance: Three classes.
CD4: >500
2 nonsevere 1.266 (1.102,1.454) 1.818 (1.130,2.926) 0.916 (0.574,1.461) 1.052 (0.656,1.687) 0.931 (0.583,1.485)
>2 nonsevere 1.369 (1.176,1.594) 1.967 (1.624,2.382) 0.991 (0.838,1.171) 1.138 (0.951,1.363) 1.007 (0.853,1.188)
>2 severe 1.565 (1.304,1.877) 2.247 (1.806,2.796) 1.132 (0.930,1.377) 1.301 (1.056,1.601) 1.150 (0.867,1.276)
Male. Resistance: Three classes.
CD4:200–500
2 nonsevere 1.327 (1.148,1.535) 1.906 (1.588,2.289) 0.960 (0.818,1.126) 1.103 (0.928,1.311) 0.976 (0.831,1.145)
>2 nonsevere 1.436 (1.224,1.685) 2.062 (1.694,2.509) 1.039 (0.873,1.235) 1.193 (0.991,1.437) 1.055 (0.888,1.254)
>2 severe 1.641 (1.358,1.982) 2.356 (1.885,2.945) 1.187 (0.970,1.452) 1.364 (1.102,1.687) 1.206 (0.988,1.472)
Male. Resistance: Three classes.
CD4: <200
2 nonsevere 1.533 (1.284,1.831) 2.202 (1.790,2.709) 1.109 (0.917,1.342) 1.275 (1.046,1.553) 1.127 (0.935,1.359)
>2 nonsevere 1.659 (1.371,2.006) 2.382 (1.912,2.968) 1.200 (0.979,1.470) 1.379 (1.117,1.701) 1.219 (0.999,1.487)
>2 severe 1.895 (1.535,2.340) 2.722 (2.141,3.461) 1.371 (1.096,1.714) 1.575 (1.243,1.997) 1.393 (1.120,1.732)
Female. No resistance. CD4: >500 2 nonsevere 0.915 (0.851,0.983) 1.314 (1.123,1.537) 0.662 (0.601,0.729) 0.760 (0.674,0.858) 0.672 (0.609,0.741)
>2 nonsevere 0.989 (0.901,1.086) 1.421 (1.199,1.684) 0.716 (0.638,0.803) 0.822 (0.718,0.942) 0.727 (0.649,0.814)
>2 severe 1.131 (0.984,1.298) 1.624 (1.328,1.985) 0.818 (0.700,0.955) 0.940 (0.791,1.116) 0.831 (0.714,0.967)
Female. No resistance.
CD4: 200–500
2 nonsevere 0.959 (0.877,1.048) 1.377 (1.169,1.622) 0.694 (0.622,0.773) 0.797 (0.670,0.908) 0.705 (0.631,0.787)
>2 nonsevere 1.037 (0.930,1.157) 1.490 (1.248,1.779) 0.750 (0.661,0.851) 0.862 (0.745,0.998) 0.763 (0.673,0.864)
>2 severe 1.185 (1.020,1.377) 1.703 (1.381,2.096) 0.857 (0.727,1.011) 0.985 (0.822,1.180) 0.871 (0.741,1.024)
Female. No resistance. CD4: <200 2 nonsevere 1.108 (0.973,1.262) 1.591 (1.319,1.919) 0.801 (0.692,0.928) 0.921 (0.786,1.078) 0.814 (0.706,0.939)
>2 nonsevere 1.199 (1.035,1.386) 1.721 (1.409,2.103) 0.867 (0.738,1.018) 0.996 (0.838,1.183) 0.881 (0.754,1.029)
>2 severe 1.370 (1.152,1.628) 1.967 (1.573,2.458) 0.991 (0.821,1.194) 1.138 (0.934,1.387) 1.007 (0.840,1.206)
Female. Resistance: Three classes.
CD4: >500
2 nonsevere 1.158 (0.990,1.354) 1.663 (1.372,2.016) 0.838 (0.705,0.995) 0.963 (0.803,1.154) 0.851 (0.716,1.011)
>2 nonsevere 1.253 (1.059,1.481) 1.799 (1.467,2.205) 0.906 (0.754,1.088) 1.041 (0.858,1.262) 0.921 (0.768,1.104)
>2 severe 1.431 (1.180,1.736) 2.056 (1.637,2.581) 1.035 (0.841,1.275) 1.190 (0.958,1.477) 1.052 (0.857,1.291)
Female. Resistance: Three classes.
CD4: 200–500
2 nonsevere 1.214 (1.031,1.429) 1.744 (1.432,2.123) 0.878 (0.735,1.049) 1.009 (0.837,1.216) 0.893 (0.747,1.066)
>2 nonsevere 1.313 (1.102,1.565) 1.886 (1.531,2.324) 0.950 (0.786,1.148) 1.092 (0.895,1.331) 0.965 (0.799,1.165)
>2 severe 1.501 (1.228,1.834) 2.155 (1.708,2.719) 1.086 (0.876,1.344) 1.247 (0.998,1.557) 1.103 (0.893,1.362)
Female. Resistance: Three classes.
CD4: <200
2 nonsevere 1.403 (1.117,1.761) 2.015 (1.566,2.591) 1.015 (0.798,1.289) 1.166 (0.914,1.486) 1.031 (0.813,1.306)
>2 nonsevere 1.517 (1.196,1.924) 2.179 (1.677, 2.831) 1.098 (0.966, 1.246) 1.261 (0.977,1.627) 1.115 (0.872,1.425)
>2 severe 1.734 (1.346,2.232) 2.490 (1.886,3.286) 1.254 (0.962,1.634) 1.441 (1.101,1.885) 1.274 (0.982,1.653)
NNRTI = non-nucleoside reverse transcriptase inhibitor; PI = protease inhibitor.
∗
The cell with a cost ratio of 1 indicates reference categories: all other ratios are estimated relative to them.
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to genotypic PI-resistance and resistance to 3 or more ARV
classes, respectively. One of the results of the regression is that
kidney insufficiency (creatinine >1.5 vs. <0.9) decreases total
costs, which is opposite to our expectations; however, the small
number of observations in this category (1.66%) prevents a
possibility to provide this inference for the whole population.
Viral load is not identified as a cost determinant. Although a
link between occurrence of detectable viremia and an increase of
annual costs would be suggestive, the design of the CORSAR
might not be capable of observing such an effect: (i) the 2-year
observation period of the survey might be too short, (ii) the
proportion of viremic patients is rather small, and (iii) most cases
have either a singular viremic “blip,” low viremia, or both, which
are associated with a low risk for subsequent virological failure orlonger observational period and a rather more restrictive
definition of viremic patients will be necessary to investigate
the long-term effects of HIV viremia in cART-treated patients on
the costs of HIV therapy.
The calculated cost ratios can be interpreted in a similar way as
the odd ratios estimated from proportional hazard models.[18]
Using relative costs, one can explore interactions among the
patients, for example, compare relative costs between patients
with varying characteristics. Particularly, combination of a low
CD4-T cell count, multiple resistance against PI or more than 1
ARV class, severe comorbidity leads to high cost cases. Table 5
and Figure 1 bring additional information and could be useful
particularly to health care payers. Some of these cases might be
prevented with improvement of ARV adherence, that is by a
patient’s ability to follow a prescribed cART plan in accordance [12] Sloan CE, Champenois K, Choisy P, et al. Newer drugs and earlier
Treskova et al. Medicine (2016) 95:26 Medicinewith the time lines.[41,42,43]
Our study has certain limitations. First, as a consequence of the
selection criteria, ARV-naïve patients were excluded from the
study and costs were calculated exclusively for patients under
ARV therapy. Therefore, we cannot provide inferences on the
costs of ARV-naïve patients or those without cART. Second,
information on transmission risks is not available in all
participating centers and, therefore, not analyzed. In conclusion,
the annual total costs per patient of HIV-related health care in
Germany continue to be high and vary greatly depending on
severity of the infection, comorbidity, and treatment attributes of
patients. The cost ratios and respective confidence intervals show
considerable variation within the stratum of CD4-T cell count,
genotypic resistance, and ARV classes. The high-cost cases are
induced by combinations of low CD4-T cell counts, resistance to
at least 3 ARVs and individualized PI-based therapy. Improve-
ment of adherence as well as development of cART regimens with
enhanced forgiveness (the ability of ARV to sustain viral
suppression, despite insufficient adherence) may prevent occur-
rence of a part of high cost cases of HIV treatment and, therefore,
they should be seen as major objectives in management of HIV
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